Actinogen Medical Seeks Quotation for Additional ASX Shares

The latest update is out from Actinogen Medical ( (AU:ACW) ).

Actinogen Medical has applied for quotation on the ASX of 62,014 new ordinary fully paid shares, to be traded under its existing ticker ACW. The securities, issued on March 5, 2026 following the exercise or conversion of existing options or other convertible securities, modestly increase the company’s listed share capital and may provide incremental funding flexibility for its ongoing activities.

While the volume of new shares is relatively small, the move demonstrates continued utilization of equity-based instruments within Actinogen Medical’s capital structure. The additional quoted securities slightly expand the company’s free float on the ASX and may have minor implications for existing shareholders in terms of dilution and daily trading liquidity.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Ltd is an Australian biotechnology company listed on the ASX under the code ACW. The company operates in the medical and healthcare sector, focusing on the development of pharmaceutical or therapeutic products, although the specific pipeline and indications are not detailed in this filing.

Average Trading Volume: 5,157,129

Technical Sentiment Signal: Sell

Current Market Cap: A$143M

For an in-depth examination of ACW stock, go to TipRanks’ Overview page.